|
Team-Based Strategies to Address Patients' Pain Needs
While team-based care is the best approach to managing patients with pain, it is not always easy, with lack of communication and education often being the biggest concerns. It is important for the entire healthcare team to work together to improve communication and to better educate patients about their pain management. Here, we examine the role of pharmacists in educating patients about their pain to optimize safe and effective treatment plans.
In this CMEOCast podcast about team-based str... |
|
|
The Role of the Pharmacist in Identifying Signs of Opioid Use Disorder
The impact of opioid on the United States and its communities is a constantly growing burden and is challenging for patients and the health care community. Pharmacists are important members of the treatment team, particularly when it comes to addressing the opioid crisis. Awareness, patient communication, and education as well as bidirectional communication with prescribers are all imperative to doing what is best for the patient. This includes identifying and using appropriate screening tools... |
|
|
Right Patient, Right Treatment, Right Time: Utilizing Early, High-Efficacy Therapies to Improve Outcomes in RRMS
Recent studies have demonstrated the benefits of early and aggressive treatment strategies in reducing disability progression and the frequency of relapses in patients with relapsing remitting multiple sclerosis (RRMS), marking a paradigm shift in the treatment of patients with RRMS. The traditional escalation approach is now often set aside in favor of the more individualized "induction" approach, which utilizes "early and aggressive" treatment with high-efficacy disease-modifying therapies (... |
|
|
Beyond the Old Paradigms: Novel Approaches to the Treatment of Chronic Idiopathic Constipation
Chronic idiopathic constipation (CIC) affects 35 million adults in the United States, making it one of the most common gastrointestinal disorders. Despite the high prevalence, CIC is often underdiagnosed and undertreated, which exacts a functional, psychosocial, and economic toll on patients and their loved ones. The current treatment goal in CIC is multi-symptom relief, but only 16% of patients with CIC are on prescription therapy, and they often only obtain partial relief, with many using la... |
|
|
Giving Shingles Immunization Your Best Shot: Implementing a Shingles Vaccination Protocol in Your Practice
Shingles, or herpes zoster, is a common secondary infection for older patients. Almost all individuals over the age of 50 are latently infected with varicella zoster virus (VZV) and therefore are at risk of developing shingles with reactivation of latent VZV. Individuals who develop shingles often experience debilitating postherpetic neuralgia (PHN), secondary skin infections, eye problems, or neurologic conditions including an increased risk of stroke.
Despite the existence of vaccines, th... |
|
|
Retooling for Modern Management of Progressive MS: An Interactive, Case-Based Activity
The approval of ocrelizumab for primary progressive multiple sclerosis (PPMS) was groundbreaking, and more recently the MS community bore witness to another major breakthrough in MS management when siponimod was approved for secondary progressive MS (SPMS). Additionally, new investigational agents such as MD1003 (high-dose biotin) and masitinib are also being evaluated for treatment of PPMS, and clinical data for both show promise for patients with SPMS.
However, despite these advances, stu... |
|
|
Looking Ahead: Integrating Emerging Therapies and Tools in Early-Stage Alzheimer's Disease
Alzheimer's disease (AD), a heterogeneous, neurodegenerative condition with an insidious onset and slow progression, is the leading cause of disability and morbidity as well as the sixth-leading cause of death in the United States. Diagnosing AD is often complicated due to its varied clinical symptomatology and unknown etiology, and currently only symptomatic therapies are available.
Recent clinical trials investigating disease-modifying therapies (DMTs) that could slow or reverse the progr... |
|
|
Live Virtual Symposium: The Road to Remission: Assessing Today's Treatment Goals in Crohn's Disease
Crohn’s disease (CD), an inflammatory bowel disease (IBD) that affects at least 780,000 people in the United States, has recently seen its management goals evolve from merely controlling flares to achieving and sustaining deep remission, which can help a patient avoid progressive bowel wall damage. The only treatments effective in achieving durable deep remission are novel targeted therapies, which makes it imperative for clinicians to have a working knowledge of these treatments and to opti... |
|
|
Hitting the Target with IL-23 Inhibitors in Psoriatic Arthiritis
Psoriatic arthritis (PsA) is a chronic, inflammatory, musculoskeletal disease with a significant impact on quality of life and functional ability. Despite the data showing the overall impact of PsA, delays in diagnosis are common, which can lead to long-term joint damage and functional disability.
In this CME Outfitters Live and OnDemand activity, expert faculty will focus on assessment, treatment, and management strategies to provide patients with the best treatment aligned with evolving e... |
|
|
Keeping the Beat: Screening and Management of High-Risk Patients with Non-Valvular Atrial Fibrillation
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, projected to affect 12 million Americans by 2030. However, a significant number of AF cases, particularly non-valvular atrial fibrillation (NVAF) remain undiagnosed, putting patients at risk for severe cardiovascular (CV) complications, including increased risk of stroke. It is imperative that clinicians identify the symptomatology of AF and effectively diagnose NVAF, as these complications can potentially be avoided by ... |
|
|
Targeted Therapy for HER2 and HER3-Positive Breast Cancer: Navigating the Evolving Treatment Landscape
Statement of Need
Breast cancer (BC) is a heterogeneous disease with human epidermal growth factor receptor 2 (HER2) overexpression and/or amplification observed in 20%-30% of cases. HER2-positive (+) BC correlates with poor clinical outcomes unless appropriately treated with targeted therapy. Despite significant therapeutic advances, many patients experience disease progression with resistance to targeted agents developing over the course of treatment.
This CME Outfitters Live and OnDe... |
|
Preceptor Mini-Series 6: The Reason I Jump - An Interprofessional Mini-Series
(See movie trailer below detailed description).
This is a 12 episode, knowledge-based, video series developed to educate both preceptors and students regarding their participation in experiential rotations in an Interprofessional setting. Each individual video episode is 8 - 14 minutes in length and builds upon the next. The series follows multiple health professional preceptors including nurses, pharmacists, physicians, speech-language-pathologists, occupational therapists, athlethic tr... |
|
|
Preceptor Mini-Series 5: Change of Heart - An Interprofessional Mini-Series
(See movie trailer below detailed description).
This is a 12 episode, knowledge-based, video series developed to educate both preceptors and students regarding their participation in experiential rotations in an Interprofessional setting. Each individual video episode is 5-10 minutes in length and builds upon the next. The series follows multiple health professional preceptors including nurses, pharmacists, physicians, speech-language-pathologists, occupational therapists, and physical t... |
|
|
Preceptor Mini-Series 4: A Glimpse Into the Life of a Community Pharmacy Preceptor
(See movie trailer below detailed description).
This 6-episode Series follows a pharmacy student and preceptor from orientation to the midpoint of a community rotation. Each video episode is 5-8 minutes in length and builds upon the next. During the Series you will experience a combination of inappropriate and quality interactions between the student, the preceptor, patients, and technicians. At moments throughout each episode, two preceptor experts provide humorous interactions and sha... |
|
|
Preceptor Mini-Series 3: Residency Preceptor's Experience
(See movie trailer below detailed description).
This 6-episode Series follows a pharmacy resident and preceptor during a clinical rotation at a hospital. Each video episode is 5-8 minutes in length and builds upon the next. During the Series you will view interactions between the resident, preceptor, residency director, and health-care team as they progress through the clinical rotation. At moments throughout each episode, two preceptor experts provide humorous interactions and share ... |
|
|
Preceptor Mini-Series 2: Adventures of Interprofessional Precepting
(See movie trailer below detailed description).
This is a 12 episode, knowledge-based, video series developed to provide educational pearls to preceptors who train students or residents on experiential rotations in an Interprofessional setting.
Each video episode is 5-8 minutes in length and builds upon the next. The series follows three health professional preceptors including a nurse, pharmacist, and physician as they precept their students in an ambulatory care setting. Through a... |
|
|
Preceptor Mini-Series 1: Preceptor Pharm Tools
(See movie trailer below detailed description).
This is a 12 episode, knowledge-based, video series developed to provide educational pearls to preceptors who train pharmacy students or residents on experiential rotations. Each video episode is 5-8 minutes in length and builds upon the next. The series follows a young preceptor and two students through a 6 week clinical rotation at a hospital. The two students are polar opposites and present unique challenges to the preceptor. At moments ... |
|
|
@MondayNightIBD OnDemand: Addressing the Cases That Challenge Your Practice
Statement of Need
Gastroenterologists are trailblazers in health care social media, and #MondayNightIBD (#MNIBD) has harnessed that energy to establish gastroenterologists as not just social media influencers but as clinical practice influencers as well. #MNIBD is not just a weekly social media conversation - it is an international platform that is moving the field forward by crowdsourcing the expertise of leading inflammatory bowel disease (IBD) experts, community clinicians, and patients ... |
|
|
Improving the Quality of Care for Patients with Atopic Dermatitis: Integrating Measurement-Based Tools Into Your Clinical Practice
Statement of Need
Attitudes about atopic dermatitis are evolving with the emergence of new and effective treatments. With the average dermatologist having not enjoyed caring for patients with AD for decades, there is little to no consensus in current practice about validated tools to assess and monitor the severity of the diseases and no consistent use of diagnostic or assessment tools. This lack of knowledge and education leads to confusion, poor recognition, and absence of assessment of AD ... |
|
|
Navigating the New Psoriasis Guidelines: Implications for Clinical Practice
Statement of Need:
The American Academy of Dermatology (AAD) and the National Psoriasis Foundation (NPF) have recently released new joint guidelines that outline best practices for the management of psoriasis (PsO) with biologics, the need for awareness and attention to comorbidities, and guidelines for pediatric PsO treatment. Clinicians must ensure that they are aware of these guidelines and of strategies to incorporate them into clinical practice, including the integration of biologic ther... |
|
|
At-Risk Patients Hidden in Plain Sight: Real-World Strategies for Screening and Treating Hepatitis B Virus
Statement of Need
Chronic hepatitis B virus (HBV) remains a global epidemic, resulting in significant morbidity and mortality. In 2015, there were 257 million people worldwide infected with HBV. In 2016, only 10.5% were diagnosed, with only 16.7% receiving treatment, and without intervention, there are 19 million deaths anticipated by the end of 2020. These numbers are startling as they exist despite the availability of effective treatment, and this is in part due to lack of clinician knowl... |
|
|
A Deeper Dive into NASH Diagnosis and Treatment: An Augmented Reality Experience
Statement of Need
Obesity and diabetes are on the rise, leading to an increased prevalence of non-alcoholic fatty liver disease (NAFLD), which in some cases may progress to non-alcoholic steatohepatitis (NASH). NAFLD effects approximately 30% of the U.S. population, with NASH effecting about 5%. NASH comes with a significant risk of progression to advanced liver fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). Disease models project that the number of individuals with end-stage live... |
|
|
What the Future Holds for NASH: An Augmented Reality Look into Disease Stating and Targeted Therapies
Statement of Need
Given the rising prevalence of non-alcoholic fatty liver disease (NAFLD) and the societal and economic burden of its aggressive subtype, non-alcoholic steatohepatitis (NASH), it is important that hepatologists and gastroenterologists are equipped with the latest tools to diagnose NASH. While there are currently no approved therapies for the treatment of NASH, several targeted therapies are being investigated in clinical trials, with high probability of being approved in the ... |
|
|
Zooming In on the Education and Empowerment of Patients in AMD Care
FDA-approved agents that target vascular endothelial growth factor (VEGF) constitute important elements of optimal management of AMD. Prior authorization (PA) requirements limit patient access to these therapies. Navigating the PA process can be frustrating for patients, and may result in treatment abandonment leading to suboptimal outcomes. Hence, there is a need for patients to become advocates of their treatment choice.
The final module of this CME Outfitters Snack series describes step ... |
|
|
Recent Clinical Trial Data on the Safety and Efficacy of Current and Emerging Therapies to Optimize Schizophrenia Management
Safe and effective treatments for schizophrenia are imperative to optimizing personalized therapy, which helps in reducing relapse and promoting functional recovery in patients with schizophrenia. Emerging data on reducing symptoms, maintaining effective therapy over long-term periods, and minimizing treatment-related metabolic side effects can guide clinicians in choosing the best therapies for their patients. In the final episode of the CMEOcast podcast series on schizophrenia, expert facult... |
|
|
Navigating Through the Latest Advances in Monoclonal Antibodies: Translating Evidence to the Care of Patients with Psoriasis
Recent years have seen an increase in the number of therapeutic monoclonal antibodies (mAbs) that are available to treat a variety of conditions caused by immune-mediated chronic inflammation such as psoriasis. Health care professionals are often presented with complex and conflicting information surrounding concepts of mAb production and immunogenicity; therefore, there is a significant need for education in this area, especially as distinguishing the relative clinical efficacy and safety pro... |
|
|
Minimizing the Burden of Prior Authorization in AMD Through Actionable Strategies and Improved Communication
The development of anti–vascular endothelial growth factor (VEGF) agents has revolutionized the treatment of age-related macular degeneration (AMD). Nevertheless, optimal management of AMD is impeded by challenges in access to FDA-approved therapies. Step therapy, a type of prior authorization (PA) instituted by the payer, mandates that more cost-effective therapies be used before more expensive alternatives, in a stepwise approach. However, applying this strategy to vision-threatening disea... |
|
|
Long-Acting Injectables for Schizophrenia: An Effective, Yet Often Underutilized Tool for Rapid Symptom Reduction and Restoration of Function
Schizophrenia is a serious and debilitating disorder that often poses a considerable challenge to clinicians. While long-acting injectables (LAIs) have emerged as a viable means to address patient nonadherence – often a component of schizophrenia management – clinicians often fail to implement the use of LAIs. Many times this is due to clinicians not being aware of updates such as the introduction of LAIs with increased dosing intervals, knowledge that is an important aspect of narrowing p... |
|
|
Keeping the Patient in the Center in AMD Care
Age-related macular degeneration (AMD) is the leading cause of legal blindness in adults over age 50, but the development of agents that target vascular endothelial growth factor (VEGF) has revolutionized its treatment. There are currently two FDA-approved agents (ranibizumab and aflibercept) and one off-label anti-VEGF agent (bevacizumab) being used to treat patients with AMD, and data from emerging anti-VEGF agents have also demonstrated efficacy in improving visual acuity. However, step the... |
|
|
Honing in on the Appeal Process to Improve Access to Anti-VEGF Therapy for Patients with AMD
Step therapy requirements have limited patient access to FDA-approved, anti–vascular endothelial growth factor (VEGF) agents for the treatment of AMD. Prior authorization requests for these therapies are commonly denied. Hence, it is important that clinicians be aware of the approaches to overcome these barriers and implement systematic and clinically supported appeals that ensure uninterrupted anti-VEGF therapy for patients with AMD.
In the third module of this CME Outfitters Snack seri... |
|
|
Current and Emerging Therapies for Schizophrenia: How MOA Affects Clinical Outcomes
Clinical trial data that addresses the safety and efficacy of antipsychotics is continuously emerging, with a focus on optimizing the management of schizophrenia. These data include the identification of strategies with novel mechanisms of action (MOAs) to effectively resolve symptoms and promote recovery while minimizing metabolic effects.
The second episode of this schizophrenia CMEOcast podcast series explores the MOAs of current and emerging therapies for schizophrenia. Expert faculty ... |
|
|
Clinical Insights on Recent Advances in Spinal Muscular Atrophy
Spinal muscular atrophy (SMA) is a leading, fatal, autosomal recessive disorder that affects approximately one in 10,000 live births. Nusinersen was approved as the first targeted therapy for SMA, and since its groundbreaking approval data has been published that demonstrates its efficacy for both infantile- and later-onset SMA populations. Additionally, recent guidelines were published that provide evidence-based recommendations for the diagnosis and management of SMA.
However, despite the... |
|
|
Pharmacy Technician Series: Cultural Competency With Transgender Patients
See webpage |
|
|
I've a Feeling Dapagliflozin Isn't in Kansas Anymore
Should you use a diabetes medication in a patient without diabetes?
A recent NEJM publication supports the use of SGLT2 inhibitors in patients with heart failure but without a diabetes diagnosis. Join October's Journal Club, lead by Dr. Raven Jackson, PharmD to learn how a historically 'diabetes drug' may now benefit a new patient population.
|
|
|
Point of Care Testing in Chronic Disease: A Training for Pharmacists
Now more than ever, pharmacists are at the front line of healthcare delivery, triaging patients with acute concerns and managing patients with chronic health conditions. This 8-hour training equips you with the necessary knowledge, skills, and resources to evaluate a presenting patient, assess the need for point of care testing, and conduct appropriate tests in the pharmacy. Don’t miss the opportunity to provide testing services your patients need.
Be prepared by taking this course that ... |
|
|
Point of Care Testing in Chronic and Infectious Disease: A Training for Pharmacists
Now more than ever, pharmacists are at the front line of healthcare delivery, triaging patients with acute concerns and managing patients with chronic health conditions. This 8-hour training equips you with the necessary knowledge, skills, and resources to evaluate a presenting patient, assess the need for point of care testing, and conduct appropriate tests in the pharmacy. Don’t miss the opportunity to provide testing services your patients need.
Be prepared by taking this course that ... |
|
|
Webinar: Expanding Pharmacy Proficiency in Transgender Care
Originally presented Monday, October 19, 2020
Throughout pharmacy, there have been gaps identified in the sensitivity training and literature available to pharmacy caregivers. The first half of this presentation will first provide cultural awareness and sensitivity training to improve interactions with this diverse patient population. The second half will provide education on transgender drug therapies, associated risk factors and monitoring to best serve this patient population.
Pharmac... |
|
|
Rockpoint-Lung-COVID-Enduring - 35621P2VRCev - 2020-09-25-01
Target Audience
This activity is intended for clinicians responsible for the daily management of patients with lung cancers.
Program Overview
Patients with underlying health conditions such as lung cancer are at greater risk for infection or complications from COVID-19. Because of this increased risk, it is important that these patients are carefully managed, with telemedicine replacing in-person visits where possible. However, monitoring patients via telemedicine requires special att... |
|
|
WEBINAR: Medical Spanish for Patient Education in the Community Pharmacy
Friday, November 13, 2020
12:00 pm ET / 11:00 am CT / 10:00 am MT / 9:00 am PT
This webinar will help pharmacists and technicians be able to utilize Spanish to improve their provision of patient education to Spanish-speaking patients in the community practice setting. During the webinar, participants will have opportunities to practice translating prescription directions from English to Spanish and learn key phrases for providing patient education in Spanish. This webinar is designed for ... |
|
|
Pharmacists Education on CBD & Cannabinoids Symposium
The Pharmacists Education on CBD & Cannabinoids Symposium will bring together pharmacists, medical professionals, scientists, legal and regulatory professionals for a two-day intensive focus on this critical topic. Whether you attend in person or online, you will have access to the best in continuing education. From chemistry and pharmacology, to the current legislation, drug approvals, and government rulings, to clinical uses, case reports, and panel discussions, the CBD and Cannabinoids Symp... |
|
|
2021 American Conference for the Treatment of HIV
The 15th annual ACTHIV is a state-of-the-science conference specifically targeted toward U.S. frontline providers of care to persons at risk of, or with HIV infection. |
|
|
WEBINAR: ¡Viva la farmacia! Basic Medical Spanish for the Community Pharmacy
Friday, October 30, 2020
12:00 pm ET / 11:00 am CT / 10:00 am MT / 9:00 am PT
This webinar will help introduce pharmacists and technicians to basic words, phrases, and concepts to help provide more culturally and linguistically appropriate care for the Spanish-speaking patient population. This webinar is designed for participants with little to no Spanish language experience, but participants of all levels of Spanish language experience are welcome to participate.
Learning Objectives:
... |
|
|
Online CE/CME - New Drug Update 2020 Part 2
Earn 5 hours of ACPE or AAFP (AMA Category 2 credit) at the location of your choosing.
At the completion of this activity, the participant will be able to:
1. Discuss the new drugs with respect to their pharmacology, pharmacokinetics, approved and unapproved indications.
2. Describe their adverse effects and drug interaction that may affect patient compliance.
3. Compare efficacy, dosage and cost to existing agents.
4. Discuss the patient oriented outcomes or evidence that may ... |
|
|
Online CE/CME - New Drug Update 2020 Part 1
Earn 5 hours of ACPE or AAFP (AMA Category 2 credit) at the location of your choosing.
At the completion of this activity, the participant will be able to:
1. Identify recent FDA drug communications, including but not limited to, labeling changes, warnings, new indications, new dosage forms and MedWatch alerts.
2. Discuss the new drugs with respect to their pharmacology, pharmacokinetics, approved and unapproved indications.
3. Describe their adverse effects and drug interaction t... |
|
|
Clostridioides Difficile in Long-Term Care: Navigating the Economic Burden and Cost-Effective Measures
Residents of long-term care facilities (LTCFs) have a high incidence of Clostridioides difficile infections (CDI). Given the financial constraints of LTCF it is not always clear the most cost-effective strategy for treating CDIs, especially considering the financial burden of many CDI treatments. This activity will review literature in relation to cost-effective CDI treatments and evaluate the implementation processes to determine the ideal scenarios for different CDI treatment options. |
|
|
Clostridioides Difficile in Long-Term Care: Improving Utilization of Evidence-based Guidelines, Clinical Trial Results, and Antibiotic Stewardship
Clostridioides difficile disproportionately impacts elderly patients, including those in long-term care facilities (LTCFs) and is associated with significant morbidity and excess healthcare costs. The burden of Clostridioides difficile infection (CDI) continues to expand beyond the inpatient arena. Evidence-based clinical practice guidelines for CDI can be applied to patients in LTCFs to improve outcomes. This module will discuss the application of CDI guidelines in LTCF patients including spe... |
|
|
Clostridioides Difficile in Long-Term Care: The Epidemiology, Challenges, and Patient Journey
There has been a dramatic change in the epidemiology of Clostridioides difficile infection (CDI) since the turn of the 21st Century. This increase is noted by the growing incidence, severity, and resistance patterns specifically occurring at a disproportionately higher frequency in geriatric patients residing in long-term care facilities (LTCF). Historically considered a nosocomial infection associated with antibiotic exposure, CDI has now also emerged in the community in populations previousl... |
|
|
5-Night Banff CME AWAY® Resort
Moose Hotel & Suites
The design of The Moose is “mountain elegance”, with warm, rich, natural materials. Located a 1 minute walk from the heart of downtown Banff, the Moose Hotel & Suites features 174 air conditioned guests rooms, with a combination of One and Two Bedroom Suites and hotel rooms. Amenities include the Meadow Spa & Pools with 10 treatment rooms and private outdoor hot pool, a bright indoor swimming pool and exercise room on the 3rd floor, and 2 spectacular rooftop hot pools... |
|
|
Obesity and COVID-19 in the Outpatient Setting: What Clinicians Need to Know
Program Overview
Multiple studies have demonstrated that patients with obesity are at increased risk for more severe COVID-19 disease. Physiological, anatomical, and psychological factors underly this increased risk and should be considered as patients with obesity are counseled about preventing SARS-CoV-2 infection and during the management of those who have COVID-19. Fortunately, guidance is being developed by the European Association for the Study of Obesity (EASO). In particular, the EASO... |
|
|
Entrustable Professional Activities: How to Train and Build Trust
Entrustable Professional Activities (EPAs) are tasks that pharmacists should be able to complete upon graduation. Unfortunately, this framework has not been fully incorporated into experiential education. This program will help preceptors understand the changing professional competencies and augment didactic learner with practical, hands-on, activities that align to the EPAs. |
|